The limitations of our study include a small number of HER2 amplified cases and GACs, the relatively short follow‐up time, and lack of well‐established evaluation criteria for HER2 expression in cervical adenocarcinoma. The gene discussed is ERBB2; the disease is cervical adenocarcinoma.